Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Anaplastic Lymphoma Kinase Inhibitors Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Status and Forecast (2016-2027)
      • 1.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Anaplastic Lymphoma Kinase Inhibitors Supply by Company

    • 2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Company
    • 2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value by Company
    • 2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Company
    • 2.4 Anaplastic Lymphoma Kinase Inhibitors Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Anaplastic Lymphoma Kinase Inhibitors Market Status by Category

    • 3.1 Anaplastic Lymphoma Kinase Inhibitors Category Introduction
      • 3.1.1 Crizotinib
      • 3.1.2 Ceritinib
      • 3.1.3 Alectinib Hydrochloride
    • 3.2 Global Anaplastic Lymphoma Kinase Inhibitors Market by Category
      • 3.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Category (2016-2021)
      • 3.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value by Category (2016-2021)
      • 3.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Anaplastic Lymphoma Kinase Inhibitors Market Status by End User/Segment

    • 4.1 Anaplastic Lymphoma Kinase Inhibitors Segment by End User/Segment
      • 4.1.1 NSCLC
      • 4.1.2 Breast Cancer
      • 4.1.3 Colorectal Cancer
      • 4.1.4 Neuroblastoma
      • 4.1.5 Ovarian Cancer
      • 4.1.6 Others
    • 4.2 Global Anaplastic Lymphoma Kinase Inhibitors Market by End User/Segment
      • 4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Anaplastic Lymphoma Kinase Inhibitors Market Status by Region

    • 5.1 Global Anaplastic Lymphoma Kinase Inhibitors Market by Region
      • 5.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Region
      • 5.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value by Region
    • 5.2 North America Anaplastic Lymphoma Kinase Inhibitors Market Status
    • 5.3 Europe Anaplastic Lymphoma Kinase Inhibitors Market Status
    • 5.4 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Status
    • 5.5 Central & South America Anaplastic Lymphoma Kinase Inhibitors Market Status
    • 5.6 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Market Status

    6 North America Anaplastic Lymphoma Kinase Inhibitors Market Status

    • 6.1 North America Anaplastic Lymphoma Kinase Inhibitors Market by Country
      • 6.1.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Country (2016-2021)
      • 6.1.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Anaplastic Lymphoma Kinase Inhibitors Market Status

    • 7.1 Europe Anaplastic Lymphoma Kinase Inhibitors Market by Country
      • 7.1.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Status

    • 8.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market by Country
      • 8.1.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Anaplastic Lymphoma Kinase Inhibitors Market Status

    • 9.1 Central & South America Anaplastic Lymphoma Kinase Inhibitors Market by Country
      • 9.1.1 Central & South America Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Anaplastic Lymphoma Kinase Inhibitors Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Market Status

    • 10.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Market by Country
      • 10.1.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Anaplastic Lymphoma Kinase Inhibitors Manufacturing Cost Analysis
    • 11.5 Anaplastic Lymphoma Kinase Inhibitors Sales Channel and Distributors Analysis
      • 11.5.1 Anaplastic Lymphoma Kinase Inhibitors Sales Channel
      • 11.5.2 Anaplastic Lymphoma Kinase Inhibitors Distributors
    • 11.6 Anaplastic Lymphoma Kinase Inhibitors Downstream Major Buyers

    12 Global Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Category and by End User/Segment

    • 12.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Anaplastic Lymphoma Kinase Inhibitors Forecast by Category
      • 12.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume Forecast by Category
      • 12.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value Forecast by Category
      • 12.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Category
    • 12.3 Global Anaplastic Lymphoma Kinase Inhibitors Forecast by End User/Segment
      • 12.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value Forecast by End User/Segment
      • 12.3.3 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by End User/Segment

    13 Global Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Region/Country

    • 13.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Region (2022-2027)
      • 13.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Xcovery Holding Company, LLC
      • 14.1.1 Company Information
      • 14.1.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.1.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Tesaro, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.2.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Takeda Pharmaceutical Co., Ltd.
      • 14.3.1 Company Information
      • 14.3.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.3.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Pfizer, Inc.
      • 14.4.1 Company Information
      • 14.4.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.4.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Oncoethix GmbH
      • 14.5.1 Company Information
      • 14.5.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.5.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Novartis AG.
      • 14.6.1 Company Information
      • 14.6.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.6.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Helsinn Therapeutics
      • 14.7.1 Company Information
      • 14.7.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.7.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 F.Hoffman-La Roche Ltd.
      • 14.8.1 Company Information
      • 14.8.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.8.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Crtierium, Inc.
      • 14.9.1 Company Information
      • 14.9.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.9.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Betta Pharmaceutcials Co., Ltd.
      • 14.10.1 Company Information
      • 14.10.2 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
      • 14.10.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Anaplastic Lymphoma Kinase Inhibitors market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Anaplastic Lymphoma Kinase Inhibitors market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Crizotinib
      Ceritinib
      Alectinib Hydrochloride

      Segmented by End User/Segment
      NSCLC
      Breast Cancer
      Colorectal Cancer
      Neuroblastoma
      Ovarian Cancer
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Xcovery Holding Company, LLC
      Tesaro, Inc.
      Takeda Pharmaceutical Co., Ltd.
      Pfizer, Inc.
      Oncoethix GmbH
      Novartis AG.
      Helsinn Therapeutics
      F.Hoffman-La Roche Ltd.
      Crtierium, Inc.
      Betta Pharmaceutcials Co., Ltd.
      Buy now